Modalis Therapeutics Corporation (TOKYO: 4883) today announced that its research article titled “Efficient LAMA1 gene activation by epigenome editing as a therapeutic approach for LAMA2-CMD” has been ...

Chinese AI startup’s release is a major update to its open-source model series, aimed at multi-language programming and ...